{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-042057","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2024-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.129329+00:00","generated_at":"2026-06-04T01:39:31.003098+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cytokinetics reports positive 48-week FOREST-HCM data on aficamten at ACC","bullets":["46 patients completed 48 weeks; 75% on 15mg or 20mg dose of aficamten.","Mean resting LVOT-G reduced by 39.6 mmHg (p<0.0001) and Valsalva LVOT-G by 53.2 mmHg.","82.2% improved by ≥1 NYHA class; no worsening class observed.","NT-proBNP decreased 63% (p<0.001); SRT-eligibility reduced 94%.","No treatment-related SAEs; modest LVEF reduction (-5.1%) with three dose adjustments."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-042057","json":"https://secwatch.observer/filing/0000950170-24-042057.json","markdown":"https://secwatch.observer/filing/0000950170-24-042057.md","text":"https://secwatch.observer/filing/0000950170-24-042057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024042057/0000950170-24-042057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024042057/cytk-20240405.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:39:31.003098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}